Bristol Questran OTC switch for cholesterol lowering set for advisory committee review.
Executive Summary
BRISTOL QUESTRAN OTC SWITCH APPLICATION ADVISORY COMMITTEE REVIEW by FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is set for Sept. 27. The committees will review data from Bristol-Myers Squibb's Rx-to-OTC switch NDAs for the cholestyramine products Questran and Questran Light (NDAs 16-640 and 19-669). Both Questran and Questran Light are intended as adjunctive therapies for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoprotein) who do not respond adequately to diet alone. Bristol's Questran NDAs are the first switch applications for cholesterol-lowering drugs to reach FDA advisory committee review.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth